{"id":217372,"date":"2025-07-08T02:29:54","date_gmt":"2025-07-08T07:29:54","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/07\/tirzepatide-tops-the-charts-for-blood-sugar-and-weight-loss-in-type-2-diabetes"},"modified":"2025-07-08T02:29:54","modified_gmt":"2025-07-08T07:29:54","slug":"tirzepatide-tops-the-charts-for-blood-sugar-and-weight-loss-in-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/07\/tirzepatide-tops-the-charts-for-blood-sugar-and-weight-loss-in-type-2-diabetes","title":{"rendered":"Tirzepatide tops the charts for blood sugar and weight loss in type 2 diabetes"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/tirzepatide-tops-the-charts-for-blood-sugar-and-weight-loss-in-type-2-diabetes.jpg\"><\/a><\/p>\n<p>A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with type 2 diabetes. Tirzepatide demonstrated the greatest efficacy for glucose control and weight loss, while liraglutide offered the lowest hypoglycemia risk.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with type 2 diabetes. Tirzepatide demonstrated the greatest efficacy for glucose control and weight loss, while liraglutide offered the lowest hypoglycemia risk.<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-217372","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/217372","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=217372"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/217372\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=217372"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=217372"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=217372"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}